1887
  1. Home
  2. Eurosurveillance
  3. Volume 28, Issue 21, 25/May/2023
  4. Article
Surveillance Open Access
Like 0
Download

Abstract

Background

Between October 2022 and January 2023, influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe with different influenza (sub)types dominating in different areas.

Aim

To provide interim 2022/23 influenza vaccine effectiveness (VE) estimates from six European studies, covering 16 countries in primary care, emergency care and hospital inpatient settings.

Methods

All studies used the test-negative design, but with differences in other study characteristics, such as data sources, patient selection, case definitions and included age groups. Overall and influenza (sub)type-specific VE was estimated for each study using logistic regression adjusted for potential confounders.

Results

There were 20,477 influenza cases recruited across the six studies, of which 16,589 (81%) were influenza A. Among all ages and settings, VE against influenza A ranged from 27 to 44%. Against A(H1N1)pdm09 (all ages and settings), VE point estimates ranged from 28% to 46%, higher among children (< 18 years) at 49–77%. Against A(H3N2), overall VE ranged from 2% to 44%, also higher among children (62–70%). Against influenza B/Victoria, overall and age-specific VE were ≥ 50% (87–95% among children < 18 years).

Conclusions

Interim results from six European studies during the 2022/23 influenza season indicate a ≥ 27% and ≥ 50% reduction in disease occurrence among all-age influenza vaccine recipients for influenza A and B, respectively, with higher reductions among children. Genetic virus characterisation results and end-of-season VE estimates will contribute to greater understanding of differences in influenza (sub)type-specific results across studies.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.21.2300116
2023-05-25
2024-12-20
/content/10.2807/1560-7917.ES.2023.28.21.2300116
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/21/eurosurv-28-21-1.html?itemId=/content/10.2807/1560-7917.ES.2023.28.21.2300116&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccines. Stockholm: ECDC. [Accessed 05 May 2023]. Available from: https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/seasonal-influenza-vaccines
  2. Hakin B, Cosford P, Harvey F. The flu immunisation programme 2013/14 – extension to children. London: Department of Health; 2013. [Accessed 05 May 2023]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/225360/Children_s_flu_letter_2013.pdf
  3. Emborg HD, Vestergaard LS, Botnen AB, Nielsen J, Krause TG, Trebbien R. A late sharp increase in influenza detections and low interim vaccine effectiveness against the circulating A(H3N2) strain, Denmark, 2021/22 influenza season up to 25 March 2022. Euro Surveill. 2022;27(15):2200278. .  https://doi.org/10.2807/1560-7917.ES.2022.27.15.2200278  PMID: 35426361 
  4. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season. Geneva: WHO. [Accessed 3 Feb 2023]. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-2023-northern-hemisphere-influenza-season
  5. European Centre for Disease Prevention and Control (ECDC), World Health Organization Regional Office for Europe (WHO/Europe). Flu News Europe. Summary week 01/2023. Stockholm: ECDC and Copenhagen: WHO/Europe; Jan 2023. Available from: https://flunewseurope.org/Archives
  6. European Centre for Disease Prevention and Control (ECDC), World Health Organization Regional Office for Europe (WHO/Europe). Flu News Europe. Summary week 02/2023. Stockholm: ECDC and Copenhagen: WHO/Europe; Jan 2023. Available from: https://flunewseurope.org/Archives
  7. European Centre for Disease Prevention and Control (ECDC), World Health Organization Regional Office for Europe (WHO/Europe). Flu News Europe. Summary week 04/2023. Stockholm: ECDC and Copenhagen: WHO/Europe; Jan 2023. Available from: https://flunewseurope.org/Archives
  8. European Union (EU). Epiconcept. I-MOVE + Protocol for hospital-based test negative case control studies to measure seasonal influenza vaccine effectiveness against influenza laboratory confirmed SARI hospitalisation among the elderly across the European Union and European Economic Area Member States. Brussels: EU; 2016. Available from: https://docs.google.com/viewer?a=v&pid=sites&srcid=ZXBpY29uY2VwdC5mcnxpbW92ZXBsdXN8Z3g6Njg0NjQwM2QxZDRlM2JmMw
  9. European Union (EU). Generic protocol for the test negative design case control studies to measure pandemic and seasonal influenza vaccine effectiveness in the European Union and European Economic Area Member States. Brussels: EU; 2015. Available from: https://drive.google.com/file/d/0Byv9pYYPpY4PM25qSXczQ3g4T0E/view
  10. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill. 2016;21(38):30348.  https://doi.org/10.2807/1560-7917.ES.2016.21.38.30348  PMID: 27684603 
  11. Emborg HD, Krause TG, Nielsen L, Thomsen MK, Christiansen CB, Skov MN, et al. Influenza vaccine effectiveness in adults 65 years and older, Denmark, 2015/16 - a rapid epidemiological and virological assessment. Euro Surveill. 2016;21(14).  https://doi.org/10.2807/1560-7917.ES.2016.21.14.30189  PMID: 27101732 
  12. European Centre for Disease Prevention and Control (ECDC). Core protocol for ECDC VEBIS studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or seasonal influenza - Version 2.0. Stockholm: ECDC; 2023 Jan. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-vaccine-effectiveness-sari-protocol-version-2.pdf
  13. Fukushima W, Hirota Y. Basic principles of test-negative design in evaluating influenza vaccine effectiveness. Vaccine. 2017;35(36):4796-800.  https://doi.org/10.1016/j.vaccine.2017.07.003  PMID: 28818471 
  14. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503-10.  https://doi.org/10.1016/0895-4356(95)00048-8  PMID: 8543964 
  15. Covenay J. FIRTHLOGIT: Stata module to calculate bias reduction in logistic regression. Boston: Boston College Department of Economics; 2015.
  16. Influenza surveillance section, Immunisation and Vaccine-Preventable Diseases Division, UK Health Security Agency. Surveillance of influenza and other seasonal respiratory viruses in winter 2021 to 2022. London: UK Health Security Agency; Jun 2022. Available from: https://www.gov.uk/government/statistics/annual-flu-reports/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-winter-2021-to-2022
  17. Kissling E, Pozo F, Martínez-Baz I, Buda S, Vilcu AM, Domegan L, et al. , I-MOVE study team. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study. Influenza Other Respir Viruses. 2023;17(1):e13069. . https://doi.org/10.1111/irv.13069  PMID: 36702797 
  18. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, Summary Europe,December 2022. Stockholm: ECDC; Jan 2023. [Accessed 3 Feb 2023]. Available from: https://www.ecdc.europa.eu/en/publications-data/influenza-virus-characterization-summary-europe-december-2022
  19. Skowronski DM, Chuang ES, Sabaiduc S, Kaweski SE, Kim S, Dickinson JA, et al. Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23. Euro Surveill. 2023;28(5):2300043. .  https://doi.org/10.2807/1560-7917.ES.2023.28.5.2300043  PMID: 36729117 
  20. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GCM, Vervaet G, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976-9.  https://doi.org/10.1126/science.1244730  PMID: 24264991 
  21. Skowronski DM, Zou M, Sabaiduc S, Murti M, Olsha R, Dickinson JA, et al. Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020. Euro Surveill. 2020;25(7):2000103.  https://doi.org/10.2807/1560-7917.ES.2020.25.7.2000103  PMID: 32098644 
  22. Dawood FS, Chung JR, Kim SS, Zimmerman RK, Nowalk MP, Jackson ML, et al. Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020. MMWR Morb Mortal Wkly Rep. 2020;69(7):177-82.  https://doi.org/10.15585/mmwr.mm6907a1  PMID: 32078591 
  23. Rose A, Kissling E, Emborg HD, Larrauri A, McMenamin J, Pozo F, et al. , European IVE group. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Euro Surveill. 2020;25(10):2000153. .  https://doi.org/10.2807/1560-7917.ES.2020.25.10.2000153  PMID: 32183932 
  24. Rosu ME, Lexmond P, Bestebroer TM, Hauser BM, Smith DJ, Herfst S, et al. Substitutions near the HA receptor binding site explain the origin and major antigenic change of the B/Victoria and B/Yamagata lineages. Proc Natl Acad Sci USA. 2022;119(42):e2211616119.  https://doi.org/10.1073/pnas.2211616119  PMID: 36215486 
  25. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season. Geneva: WHO. [Accessed 14 Mar 2023]. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season
  26. Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371:m3731.  https://doi.org/10.1136/bmj.m3731  PMID: 33082154 
  27. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4.  https://doi.org/10.1001/jama.2013.281053  PMID: 24141714 
Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Esther+Kissling&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kissling Esther</a>, <a href="/search?value1=Marine+Maurel&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Maurel Marine</a>, <a href="/search?value1=Hanne-Dorthe+Emborg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Emborg Hanne-Dorthe</a>, <a href="/search?value1=Heather+Whitaker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Whitaker Heather</a>, <a href="/search?value1=Jim+McMenamin&option1=author&noRedirect=true" class="nonDisambigAuthorLink">McMenamin Jim</a>, <a href="/search?value1=Jennifer+Howard&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Howard Jennifer</a>, <a href="/search?value1=Ramona+Trebbien&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Trebbien Ramona</a>, <a href="/search?value1=Conall+Watson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Watson Conall</a>, <a href="/search?value1=Beth+Findlay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Findlay Beth</a>, <a href="/search?value1=Francisco+Pozo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pozo Francisco</a>, <a href="/search?value1=Amanda+Bolt+Botnen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bolt Botnen Amanda</a>, <a href="/search?value1=Ciaran+Harvey&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Harvey Ciaran</a>, <a href="/search?value1=Angela+Rose&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rose Angela</a>, <a href="/search?value1=European+IVE+group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">European IVE group</a></span>. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. <a href="/content/ecdc">Euro Surveill.</a> 2023;28(21):pii=2300116. <a href="https://doi.org/10.2807/1560-7917.ES.2023.28.21.2300116" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2023.28.21.2300116</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 15 Feb 2023;&nbsp;&nbsp; <span class="generated">Accepted</span>: 21 Mar 2023 </span> </p>
/content/10.2807/1560-7917.ES.2023.28.21.2300116
/content/10.2807/1560-7917.ES.2023.28.21.2300116
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error